Success Metrics

Active Trials
8(100%)

Phase Distribution

Ph phase_2
4
50%
Ph phase_4
1
13%
Ph phase_1
3
38%

Phase Distribution

3

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
3(37.5%)
Phase 2Efficacy & side effects
4(50.0%)
Phase 4Post-market surveillance
1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

8

trials recruiting

Total Trials

8

all time

Status Distribution
Active(8)

Detailed Status

Recruiting7
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
8
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 13 (37.5%)
Phase 24 (50.0%)
Phase 41 (12.5%)

Trials by Status

active_not_recruiting113%
recruiting788%

Recent Activity

8 active trials
Showing 5 of 8
recruitingphase_2

A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)

NCT05851924
recruitingphase_1

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

NCT06483555
recruitingphase_2

Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma

NCT07163273
recruitingphase_1

Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis

NCT07030283
recruitingphase_2

NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm Trial

NCT07077551
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05851924Phase 2

A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting
NCT06483555Phase 1

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

Recruiting
NCT07163273Phase 2

Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting
NCT07030283Phase 1

Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis

Recruiting
NCT07077551Phase 2

NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm Trial

Recruiting
NCT07020468Phase 4

Neoadjuvant Therapy （NALIRIFOX） for Locally Advanced Colon and Upper Rectal Cancer

Active Not Recruiting
NCT06816914Phase 2

Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial

Recruiting
NCT06736717Phase 1

Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer

Recruiting

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8